Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia.
暂无分享,去创建一个
Francisco Cervantes | Xabier Agirre | F. Prósper | X. Agirre | J. A. Castillejo | A. Torres | A. Jiménez-Velasco | L. Cordeu | L. Gárate | Edurne San José-Enériz | A. Heiniger | J. Román-Gómez | F. Cervantes | Leire Garate | Lucia Cordeu | Antonio Torres | Anabel Heiniger | Felipe Prosper | G. Navarro | Jose Roman-Gomez | Antonio Jimenez-Velasco | Juan A Castillejo | German Navarro | Edurne San Jose-Eneriz | J. Román-Gómez | Lucía Cordeu
[1] Jian Zhang,et al. SPAN‐Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically , 2006, International Journal of Cancer.
[2] J. Hasford,et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.
[3] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[4] R. Rizwana,et al. CpG methylation reduces genomic instability. , 1999, Journal of Cell Science.
[5] M. Ehrlich,et al. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. , 1999, Mutation research.
[6] A. Sette,et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.
[7] A. Green,et al. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. , 2003, Blood.
[8] M. Ehrlich,et al. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer , 2005, Genes, chromosomes & cancer.
[9] E. Owen-Jones,et al. Expression of testicular genes in haematological malignancies , 1999, British Journal of Cancer.
[10] A. Giuliano,et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma , 1994, Cancer.
[11] S. Nishizuka,et al. Demethylation of MAGE promoters during gastric cancer progression , 2004, British Journal of Cancer.
[12] P. Coulie,et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen , 2005, The Journal of experimental medicine.
[13] Y. Tsao,et al. Sub-tenon anesthesia for segmental scleral buckling and assessment of postoperative pain. , 2002, Chang Gung medical journal.
[14] M. Maio,et al. Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma , 2002, Journal of immunotherapy.
[15] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[16] D. Heimburger,et al. Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression. , 2001, Human pathology.
[17] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Lane,et al. Identification of a putative RNA helicase in E.coli. , 1990, Nucleic acids research.
[19] Hansoo Lee,et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. , 2003, Biochemical and biophysical research communications.
[20] 倉繁 拓志. NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma: Correlation with Tumor Grade , 2001 .
[21] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[22] E. Sabo,et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] T. Brümmendorf,et al. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. , 2006, Cancer research.
[24] S. Courtois,et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene , 2004, Immunogenetics.
[25] M. Cravo,et al. Global DNA hypomethylation in breast carcinoma , 1999, Cancer.
[26] J. McCluskey,et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] Zhi-Ren Liu,et al. Phosphorylations of DEAD Box p68 RNA Helicase Are Associated with Cancer Development and Cell Proliferation , 2005, Molecular Cancer Research.
[28] S. Salesse,et al. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells , 2004, Leukemia.
[29] G. Canellos,et al. Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.
[30] Jorge Cortes,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.
[31] Yong Bok Park,et al. Activation of human cancer/testis antigen gene, XAGE‐1, in tumor cells is correlated with CpG island hypomethylation , 2005, International journal of cancer.
[32] A. Kaneda,et al. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation , 2004, Cancer science.
[33] M. Maio,et al. Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.
[34] T. Boon,et al. Identification on a human sarcoma of two new genes with tumor-specific expression. , 2000, Cancer research.
[35] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[36] D. H. Mellor,et al. Real time , 1981 .
[37] K. Pantel,et al. MAGE-A gene expression pattern in primary breast cancer. , 2001, Cancer research.
[38] A. Tabilio,et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial , 2005, The Lancet.
[39] B. Czepulkowski,et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias , 2002, Leukemia.
[40] B. Calabretta,et al. The biology of CML blast crisis. , 2004, Blood.
[41] A. Hasegawa,et al. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. , 2001, Blood.
[42] R. Jaenisch,et al. Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.
[43] Lloyd J. Old,et al. Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.
[44] F. Prósper,et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia , 2005, Oncogene.
[45] Francisco Cervantes,et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .